• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

CompuCyte Corporation and Program in Cellular and Molecular Medicine at Children's Hospital Boston Announce Joint Program for Quantitative Imaging Cytometry Research Services

Posted on: Tuesday, 10 March 2009, 12:00 CDT

BOSTON, March 10 /PRNewswire/ -- CompuCyte Corporation and the Program in Cellular and Molecular Medicine at Children's Hospital Boston (also known as the Immune Disease Institute) today announced the establishment of a joint Quantitative Imaging Cytometry program. The Program in Cellular and Molecular Medicine is an affiliate of Harvard Medical School (HMS) and is located in the Longwood Medical Area. Under the terms of the agreement, CompuCyte will make its proprietary laser scanning cytometry instrumentation and technical support programs available to trained personnel, and will provide quantitative imaging cytometry and analysis services to the larger Longwood Medical Area community.

"The joint program with CompuCyte gives our facility a new and powerful asset to offer the HMS research community. CompuCyte's instrumentation provides the ability to combine the quantitative data traditionally generated through flow cytometry with laser-scanned images of cells and tissues, without the traditional flow requirement for harsh sample-processing and the unwanted disturbance of native cells and tissue architecture normally associated with traditional cytometry," explained Dr. Natasha Barteneva, Director of the Flow and Imaging Cytometry Resource of the Program in Cellular and Molecular Medicine and manager of the joint program. "The agreement with CompuCyte expands our capacity in quantitative imaging cytometry and reinforces our commitment to providing our researchers access to the most advanced analytical technologies," stated Dr. Margaret Bradley, Chief Scientific Administrative Officer.

"Laser Scanning Cytometry (LSC) technology has become a gold standard in quantitative automated analysis of intact adherent cells, tissue specimens, tissue microarrays and small cellular samples, such as small needle aspirates," explained Dr. Elena Holden, CompuCyte's President and Chief Executive Officer. "The reputation of the Program in Cellular and Molecular Medicine for quality and scientific vigor is well known. We are enthusiastic about the opportunity to collaborate with their Flow and Imaging Cytometry Resource and to add our proprietary LSC technology to their existing infrastructure."

The Program in Cellular and Molecular Medicine at Children's Hospital Boston (also known as the Immune Disease Institute) is a non-profit research institution academically affiliated with Harvard Medical School, recognized worldwide for its discoveries that increase the body's ability to fight disease. Its mission is fundamental biomedical research to improve human health, harness inflammation, and strengthen immune defense.

CompuCyte Corporation, a private company headquartered in Westwood, Massachusetts, is a pioneer and leader in the development of quantitative imaging cytometry instrumentation based on patented laser scanning cytometry technology. The company's iCyte(R), iCys(R), and iColor(R) cytometers enable true quantitative cytometric image analysis of cellular and tissue specimens in life science research, drug safety, toxicology studies, biomarker discovery and clinical trials.

SOURCE CompuCyte Corporation

Source: PR Newswire

More News in this Category